ArticleMedicine2026
Peritoneal dialysis-associated peritonitis caused by Ureaplasma urealyticum: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleUreaplasma urealyticum is a rare cause of peritoneal dialysis-associated peritonitis (PDAP) that may be missed by routine culture. Here, we report a culture-negative case in which targeted next-generation sequencing (tNGS) supported rapid pathogen identification and treatment adjustment. PATIENT CONCERNS: A 41-year-old woman receiving continuous ambulatory peritoneal dialysis for >10 years presented with acute abdominal pain, cloudy dialysate, fever, and neutrophilic dialysate leukocytosis. The patient was diagnosed with PDAP. DIAGNOSES: Repeated bacterial and fungal cultures and acid-fast staining were negative. tNGS of peritoneal dialysate detected U urealyticum, which is considered the most likely causative pathogen.
interventionsEmpirical vancomycin plus ceftazidime, followed by vancomycin plus meropenem, was ineffective. The treatment was changed to oral doxycycline plus intraperitoneal levofloxacin after the tNGS results became available. A vaginal U urealyticum isolate was subsequently resistant to levofloxacin; therefore, levofloxacin was replaced with intravenous azithromycin. OUTCOMES: The abdominal pain resolved, the dialysate cleared, inflammatory markers decreased, the PD catheter was retained, and no recurrence occurred during the 1-month follow-up period. LESSONS: In persistent culture-negative PDAP that does not respond to cell wall-active antibiotics, clinicians should consider cell wall-deficient organisms such as Ureaplasma. tNGS may complement conventional microbiological testing, but the results should be interpreted in the clinical context and, when possible, confirmed by an independent method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.